Alpha-1 Antitrypsin Inhalation Therapy Delivery System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating alpha-1 antitrypsin deficiency (AATD) and related conditions are limited, with high costs and restricted access to AAT products, and there is a lack of awareness and research on the broader health implications of AAT levels in non-AATD patients, leading to inadequate management of comorbid conditions.
Innovation Solution
A method for determining AAT deficiency or low circulating AAT levels in patients, followed by administration of AAT to maintain levels within a therapeutic range, using various forms of AAT supplementation including inhalation, infusion, or oral administration, to treat a range of conditions beyond traditional AATD, such as Alzheimer's, autoimmune diseases, and cancer, by inhibiting neutrophil elastase and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAT products are administered intravenously to treat AATD, then treatment effectiveness is improved, but treatment cost increases
Solution Approach 1:
The patent changes the administration parameter from intravenous to inhalation, transforming the delivery method to reduce treatment costs while maintaining therapeutic effectiveness through direct lung delivery of AAT
Solution Approach 2:
The patent extracts the AAT treatment from the expensive intravenous plasma product category and formulates it as an inhalation therapy, separating the therapeutic agent from the costly delivery system to reduce overall treatment cost
2Reliability
If AAT products are administered intravenously to treat AATD, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent extracts the AAT treatment from the complex intravenous infusion system and formulates it as a simple inhalation therapy that can be administered through a nebulizer or inhaler, dramatically reducing administration complexity
Solution Approach 2:
The patent employs disposable inhalation devices or nebulizers that can be easily discarded after use, eliminating the need for complex, expensive, and difficult-to-clean intravenous infusion equipment
3Reliability
If AAT products are administered intravenously to treat AATD, then treatment effectiveness is improved, but ease of operation decreases
Solution Approach 1:
The patent extracts the AAT treatment from the complex intravenous infusion process and formulates it as a simple inhalation therapy that patients can administer independently without requiring medical personnel
Solution Approach 2:
The patent enables patients to self-administer AAT therapy through inhalation devices, eliminating the need for complex intravenous infusions that require trained medical staff, thereby significantly improving ease of operation
4Reliability
If AAT products are administered intravenously to treat AATD, then treatment effectiveness is improved, but loss of time increases
Solution Approach 1:
The patent extracts the AAT treatment from the time-consuming intravenous infusion process and formulates it as a rapid inhalation therapy that can be administered in minutes rather than hours
Solution Approach 2:
The patent skips the lengthy intravenous infusion process and delivers AAT directly to the lungs through inhalation, dramatically reducing the time required for treatment while maintaining effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables broader treatment of conditions associated with low AAT levels, improving quality of life and reducing the severity of diseases like Alzheimer's, autoimmune disorders, and cancer, while potentially lowering treatment costs and increasing awareness and research into AAT's role in overall health.
Implementation Method 1
AAT is a member of the serine protease inhibitor superfamily known as Serpins
Implementation Method 2
AAT has the potential to treat many other conditions. However, as a powerful inhibitor of neutrophils, neutrophil elastase, neutrophil extracellular traps, inflammation, and oxidative stress
Data Source
AI summary
A method of preventing and/or treating a plurality of diseases by determining if the patient is alpha-1 antitrypsin deficient by obtaining a biological sample from the patient and performing a genotyping assay on the biological sample to determine if the patient has a SERPINA1 alpha-1 antitrypsin deficient genotype or measuring the circulating level of alpha-1 antitrypsin in the sample. If the patient has a SERPINA1 alpha-1 antitrypsin deficient genotype or low levels of circulating alpha-1 antitrypsin, then alpha-1 antitrypsin is administered to the patient.